---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006641"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:30:40.323342+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference

## Summary
- Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).
- Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.
- CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program.

## SEC filing metadata
- accession: 0001683168-25-006641
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/0001683168-25-006641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006641
- JSON: https://secwatch.observer/filing/0001683168-25-006641.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.